[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 10 sources · 3 days · First seen · Last updated

Novartis financial performance and guidance updates

Overview

In the second quarter of 2026, Novartis reported a 1% increase in net sales, driven by priority brands such as Kisqali and Kesimpta. Despite this growth, the company saw a 19% decline in net income and flat core operating income.

By the third quarter, Novartis raised its full-year guidance for adjusted operating profit to expect low single-digit growth, reversing a previous forecast of a decline. This shift followed strong sales in cancer and multiple sclerosis medications. However, net profit dropped 70% to $1.2 billion, largely due to a $1.9 billion write-down following the failure of a clinical trial for the experimental neuromuscular treatment del-desiran.

Entities

Novartis · Vas Narasimhan · FDA · Avidity Biosciences · DroneShield

Timeline

  1. [BUSINESS] 8 sources
    Novartis raises profit guidance following strong Q3 sales

    Novartis raised its 2026 operating profit guidance following strong Q3 sales, despite a 70% net profit drop caused by a $1.9 billion write-down on a failed clinical trial.

  2. [BUSINESS] 2 sources
    Novartis reports Q2 sales growth driven by priority brands

    Novartis saw Q2 2026 net sales grow by 1% (3% in USD), fueled by brands like Kisqali and Scemblix, while reaffirming its full-year guidance.

Sources

aktiencheck.de · cash.ch · financialmarket.ro · financije.hr · finanzen.ch · it-boltwise.de · moneycab.com · powergame.gr · sustainablefish.org · tele1.com.tr